Finally, kidney disease meets a true opponent
We’re pioneering precision-based medicines to revolutionize the treatment of kidney diseases.
A global epidemic with an innovation gap
Chronic kidney disease (CKD) affects 780 million people globally–that’s one in every ten people. Progression to end-stage kidney disease is common, and severely impacts quality of life. Despite this, fewer than 1% of all research programs across the biopharmaceutical industry are focused on reducing the substantial burden of CKD.
Learn more about the problem we aim to solve
780M
People worldwide with CKD
10M
People die annually from kidney disease worldwide
<1%
Of all active pipeline programs in the biopharmaceutical industry are for kidney diseases
Our Precision Medicine Approach to Treat Kidney Disease
We are applying precision medicine to discover, develop and commercialize disease-modifying kidney disease treatments. We believe our approach enables us to uncover subsets of patients based on genetic and environmental factors within heterogenous kidney diseases.
We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet medical needs. Our lead program, GFB-887, is designed to treat people with focal segmental glomerulosclerosis (FSGS) caused by an overactivation of the TRPC5-Rac1 pathway.
Our Precision Medicine Product Engine: Integrating Kidney Genetics & Biology
Our product engine allows us to discover, validate and drug novel targets while identifying patient subsets most likely to respond to our treatments.
There are so many people with kidney disease, me included, who are struggling every day to live life and to live it with some sense of quality. We need to find solutions because dialysis and transplants are not great solutions.
Living with FSGS
A bold mission to transform the lives of people living with kidney disease
Our Mission
To deliver disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases.
Our Vision
We aspire to save kidneys and end dialysis.
The Feeder Interview Series
Check out our new interview series, The Feeder. We’re speaking with people impacted by kidney disease, and a wide range of experts who are driving change, innovation and hope in the kidney space.
Latest news
See all news & features
04.20.2021
Goldfinch Bio Expands Board of Directors with Appointments of Meryl Zausner, Hon. William “Mo” Cowan and Tyrell Rivers, Ph.D.
Read More
11.19.2020
Goldfinch Bio Announces Appointment of Robin A. Walker, J.D., as Chief Legal Officer
Read More
10.22.2020
Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases
Read More
Become a Finch
Join Us!
We aspire to be the world’s leading precision medicine kidney company – dedicated to our mission, focused on pursuing world-class science and fully committed to improving the lives of people with kidney disease.